M7437 / EMD Serono - LARVOL DELTA

M7437, a novel anti-Ly6E antibody-drug conjugate (ADC) with topoisomerase 1 (TOP1) inhibitor payload: Preclinical antitumor activity and safety (AACR 2026) - "M7437 demonstrated strong antitumor activity in PDX models, including a broad range of indications and a potent bystander effect indicating the potential to treat tumors with heterogeneous target expression. Together with an acceptable toxicity profile and favorable pharmacokinetic properties, the observed preclinical data support the clinical development of M7437."

ADC • Preclinical • Breast Cancer • Gastric Cancer • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer • LY6E • TOP1

Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=138 | Recruiting | Sponsor: EMD Serono Research & Development Institute, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human • Breast Cancer • Gastric Cancer • Head and Neck Cancer • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer • LY6E

Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=138 | Not yet recruiting | Sponsor: EMD Serono Research & Development Institute, Inc.

First-in-human • New P1 trial • Breast Cancer • Gastric Cancer • Head and Neck Cancer • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Ovarian Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer • LY6E

Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=138 | Not yet recruiting | Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

First-in-human • New P1 trial • Solid Tumor